Kazia Share Price, page-739

You are confusing and potentially confused … I assume you are referring to CHM’s ONC201 when you write “It’s results are much better than the GDC for the same phase …”

Based on the trial overview for ONC201, https://clinicaltrials.gov/ct2/results?cond=onc201&term=&cntry=&state=&city=&dist=, there are no results for ONC201 in newly diagnosed GBM but only in recurrent GBM.
As you probably know, paxalisib’s Phase II results were in unmethylated, newly diagnosed GBM.

Paxalisib’s results in recurrent GBM and in DIPG are still outstanding.

This means there is currently no trial data in any indication that would allow for an indirect treatment comparison between paxalisib and ONC201.

There is no evidence to substantiate your statement. At least not for now.
If there is, please share it.